# CURANEX PHARMACEUTICALS INC (CURX)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/CURX/

- Reporting holders: 11
- Reported value: $114.3K
- Shares held by institutions: 429,367 of 31,364,812 outstanding
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [CITADEL ADVISORS LLC](https://holderbook.com/funds/1423053-citadel-advisors-llc/) | $50.5K | 190,516 | 0.0% | 4 |
| [Virtu Financial LLC](https://holderbook.com/funds/1533964-virtu-financial-llc/) | $14.0K | 51,236 | 0.0% | 1 |
| [RENAISSANCE TECHNOLOGIES LLC](https://holderbook.com/funds/1037389-renaissance-technologies-llc/) | $13.8K | 52,000 | 0.0% | 1 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $10.2K | 38,288 | 0.0% | 4 |
| [JANE STREET GROUP, LLC](https://holderbook.com/funds/1595888-jane-street-group-llc/) | $8.3K | 31,215 | 0.0% | 1 |
| [TWO SIGMA INVESTMENTS, LP](https://holderbook.com/funds/1179392-two-sigma-investments-lp/) | $7.3K | 27,354 | 0.0% | 3 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](https://holderbook.com/funds/1446194-susquehanna-international-group-llp/) | $3.9K | 14,657 | 0.0% | 1 |
| [Ground Swell Capital, LLC](https://holderbook.com/funds/1534450-ground-swell-capital-llc/) | $3.4K | 12,638 | 0.0% | 1 |
| [CITIGROUP INC](https://holderbook.com/funds/831001-citigroup-inc/) | $2.4K | 8,957 | 0.0% | 2 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $400 | 1,506 | 0.0% | 4 |
| [Tower Research Capital LLC (TRC)](https://holderbook.com/funds/1533421-tower-research-capital-llc-trc/) | $265 | 1,000 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 11 | $114.3K |
| Q1 2026 | 8 | $167.6K |
| Q4 2025 | 11 | $140.5K |
| Q3 2025 | 10 | $225.9K |